Johnson & Johnson’s 2025 strategy: breakthrough cardiac ablation, a major FDA push for Stelara in Crohn’s disease, and resilient financials despite litigation.

Johnson & Johnson reported a strong Q2 performance, exceeding market expectations and raising its full-year guidance for 2025, driven by growth in its medtech business.